Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 13/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225146 | 1.00 | CHRM4 (0.52) | CHRM4CHRM2CYP2D6CYP3A4ACHE | |
| SCHEMBL21225102 | 1.00 | CHRM4 (0.52) | CHRM4CHRM2CYP2D6CYP3A4ACHE | |
| SCHEMBL21225147 | 1.00 | CHRM4 (0.52) | CHRM4CHRM2CYP2D6CYP3A4ACHE | |
| SCHEMBL29864688 | 1.00 | CHRM4 (0.52) | CHRM4CHRM2CYP2D6CYP3A4ACHE | |
| SCHEMBL21224973 | 1.00 | CHRM4 (0.52) | CHRM4CHRM2CYP2D6CYP3A4ACHE | |
| SCHEMBL21225120 | 0.92 | CHRM4 (0.49) | CHRM4CHRM2CYP2D6ACHE | |
| SCHEMBL21225013 | 0.92 | CHRM4 (0.49) | CHRM4CHRM2CYP2D6ACHE | |
| SCHEMBL21225119 | 0.92 | CHRM4 (0.49) | CHRM4CHRM2CYP2D6ACHE | |
| SCHEMBL21225017 | 0.92 | CHRM4 (0.49) | CHRM4CHRM2CYP2D6ACHE | |
| SCHEMBL21225015 | 0.92 | CHRM4 (0.49) | CHRM4CHRM2CYP2D6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746421-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11414406-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3746421-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200369650-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| WO-2019152809-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414406-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP2D6 702/4885 |
| US-20200369650-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | CHRM4 3/4885CHRM2 1/4885CYP2D6 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.